Bimatoprost IOL Shows 12-Month IOP Reductions

Clinical Scorecard: Bimatoprost IOL Shows 12-Month IOP Reductions

At a Glance

Category	Detail
Condition	Mild-to-moderate open-angle glaucoma (OAG) or ocular hypertension (OHT) in patients undergoing cataract surgery
Key Mechanisms	An investigational intraocular lens system uses two bimatoprost-eluting pads designed to provide continuous drug release for up to 3 years.
Target Population	Adults with mild-to-moderate OAG or OHT undergoing cataract surgery; the trial included 104 evaluable patients.
Care Setting	Cataract surgery using standard phacoemulsification, with the investigational system implanted in the capsular bag.

Key Highlights

At 12 months, the presentation reported approximately 9 mmHg (about 35%) mean IOP reduction from baseline across treatment groups.
At 12 months, 98% of patients in the 78-μg BIM-IOL group and 96% in the 39-μg group remained free of additional IOP-lowering medication.
The control group received a commercially available IOL and twice-daily topical timolol 0.5%; all control patients remained free of additional medication while receiving timolol.
Adverse events were reported in 41% of the 78-μg group, 43% of the 39-μg group, and 37% of the control group; no serious adverse events, secondary surgical interventions, or explantations were reported.
The 12-month analysis was interim; longer follow-up is needed to assess durability and safety.

Guideline-Based Recommendations

Diagnosis

The trial enrolled adults with mild-to-moderate OAG or OHT undergoing cataract surgery; all IOP-lowering medications were washed out before baseline measurements.

Management

The BIM-IOL system was implanted during standard phacoemulsification and compared with a commercially available IOL plus topical timolol 0.5%.
The BIM-IOL system remains investigational and has not received FDA approval.

Monitoring & Follow-up

The trial assessed time-matched IOP at 8 AM and 10 AM at 2, 6, and 12 weeks, with additional outcomes including IOP through 3 years, visual performance, and safety.
The investigators identified longer follow-up as necessary to assess durability of IOP control and safety.

Risks

The 12-month findings are interim, and applicability to patients with more advanced glaucoma is undetermined.
Complete masking of the operating surgeon was not possible, although IOP measurements were masked.

Patient & Prescribing Data

The prospective, multicenter, randomized, double-masked, controlled phase 1/2 trial included 104 evaluable adults: 88 (85%) with mild-to-moderate OAG and 16 (15%) with OHT. Mean age was 70.2 years; 51% were female.

Patients were assigned to BIM-IOL containing 78 μg (n=51), BIM-IOL containing 39 μg (n=23), or a commercially available IOL with twice-daily topical timolol 0.5% (n=30). BIM-IOL recipients used artificial tears twice daily. At 12 months, 48, 22, and 30 patients, respectively, were included in the efficacy analysis.

Clinical Best Practices

Interpret the reported efficacy and safety in the context of an interim 12-month analysis.
Note that trial enrollment was limited to patients with OHT or mild-to-moderate OAG; findings in more advanced disease were not established.
Consider the study's medication washout and masking limitations when interpreting its results.